Supernus bulks up its Parkinson’s portfolio with Adamas takeoverSupernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas Share XSupernus bulks up its Parkinson’s portfolio with Adamas takeoverhttps://pharmaphorum.com/news/supernus-bulks-up-its-parkinsons-portfolio-with-adamas-takeover/
Scientific study finds music can ‘tune out pain’A study has found that listening to a specially composed music track can achieve “clinically significant” reductions in Share XScientific study finds music can ‘tune out pain’https://pharmaphorum.com/news/scientific-study-finds-music-can-tune-out-pain/
EU panel rejects Pfizer’s tanezumab for osteoarthritis painAny lingering hope that Pfizer may finally get a regulatory approval for its nerve growth factor (NGF) inhibitor Share XEU panel rejects Pfizer’s tanezumab for osteoarthritis painhttps://pharmaphorum.com/news/eu-panel-rejects-pfizers-tanezumab-for-osteoarthritis-pain/
Lilly taps Lycia for protein degrader tech in $1.6bn dealEli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 billion-plus deal Share XLilly taps Lycia for protein degrader tech in $1.6bn dealhttps://pharmaphorum.com/news/lilly-taps-lycia-for-protein-degrader-tech-in-1-6bn-deal/
Older people ‘more likely to engage with digital physiotherapy care’Researchers in the US have found that older people are far more likely to engage with digital physiotherapy Share XOlder people ‘more likely to engage with digital physiotherapy care’https://pharmaphorum.com/news/older-people-more-likely-to-engage-with-digital-physiotherapy-care/
Thumbs-down from FDA experts for Pfizer/Lilly’s painkiller tanezumabAfter more than a decade of fraught clinical development it looks like the end of the line for Share XThumbs-down from FDA experts for Pfizer/Lilly’s painkiller tanezumabhttps://pharmaphorum.com/news/fda-experts-give-thumbs-down-for-pfizer-lillys-painkiller-tanezumab/
FDA worried about Pfizer/Lilly pain drug safety ahead of key meetingAfter a long and troubled development the fate of Pfizer/Lilly’s tanezumab painkiller injection is in the balance ahead Share XFDA worried about Pfizer/Lilly pain drug safety ahead of key meetinghttps://pharmaphorum.com/news/fda-worried-pfizer-lilly-pain-drug-safety-ahead-of-key-meeting/
Kaia Health creates new ‘front door’ for MSK pain servicesKaia Health is adding to its offering for patients with musculoskeletal (MSK) pain via a partnership with Premium Share XKaia Health creates new ‘front door’ for MSK pain serviceshttps://pharmaphorum.com/news/kaia-health-creates-new-front-door-for-msk-pain-services/
Lilly adds to pain pipeline with Asahi Kasei licensing dealUS drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has Share XLilly adds to pain pipeline with Asahi Kasei licensing dealhttps://pharmaphorum.com/news/lilly-adds-to-pain-pipeline-with-asahi-kasei-licensing-deal/
